Oppenheimer initiated coverage on Abbott Labs with a new price target
$ABT
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $143.00 | Market Perform | Leerink Partners |
| 10/8/2024 | $130.00 | Outperform | Oppenheimer |
| 9/19/2024 | $131.00 | Overweight | Piper Sandler |
| 7/30/2024 | Buy → Hold | Edward Jones | |
| 5/30/2024 | $121.00 | Buy | Goldman |
| 7/21/2023 | Underperform → Peer Perform | Wolfe Research | |
| 5/30/2023 | $112.00 | Overweight → Equal-Weight | Morgan Stanley |
| 4/20/2023 | $125.00 → $127.00 | Overweight | Barclays |
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica
Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status.Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes.CHICAGO, June 20, 2025 /PRNewswire/ -- Late-breaking research presented at the American Diabetes Association's 85th Scientific Sessions showed that Abbott's (NYSE:ABT) Healthy Food Rx "food is medicine" program helped people living with diabetes
The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussionThe test produces lab-quality results in 15 minutesClinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency roomThe test can be used to help evaluate patients up to 24 hours after injuryMISSISSAUGA, ON, June 16, 2025 /CNW/ -- Abbott (NYSE:ABT) announced today that Health Canada has approved the company's i-STAT TBI test cartridge for use with whole blood, helping clinicians to assess suspected concussio
ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica
ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 406th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio
First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increaseReported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increaseABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2025. First-quarter sales increased 4.0 percent on a reported basis, 6.9 pe
For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime
11-K - ABBOTT LABORATORIES (0000001800) (Filer)
SD - ABBOTT LABORATORIES (0000001800) (Filer)
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00
Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00
Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00
This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)